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Coronary artery disease is almost ubiquitous in our pop-
ulation but comes in a wide variety of shapes and sizes. For
decades, a simple but powerful concept has guided decision
making in prescribing therapies: the highest risk forms of the
disease require the most aggressive treatments, whereas
the lowest risk forms warrant only the most gentle. That is,
the patient with 3-vessel disease and left ventricular
dysfunction requires bypass surgery, whereas the patient with
minimal coronary irregularities requires only a statin or
aspirin. Even within the context of patients receiving medical
therapy without revascularization, a wide range of treatments
are now or will soon be available, including aspirin, mild or
strong P2Y12 inhibitors, statins, and PCSK9 inhibitors to
moderate or low low-density lipoprotein targets, interven-
tions to augment high-density lipoprotein, antihypertensiveSee page 2296drugs to various levels of BP reduction, angiotensin-
converting enzyme inhibitors and angiotensin-receptor
blockers, and drugs to inhibit vascular inﬂammation. To
prescribe individualized therapy, we need an accurate
assessment of risk. The study by Versteylen et al. (1) in the
this issue of the Journal demonstrates that quantitative
information derived from the direct imaging of atheroscle-
rotic lesions by computed tomography angiography (CTA)
has the potential to deﬁne risk more accurately and therefore
guide therapy in a way that has previously not been possible.
A large body of literature has accumulated in which
characteristics of an individual plaque susceptible to rupture
or erosion (2) with subsequent thrombus formation are
deﬁned, with the thought that these plaques might be
detected by imaging methods and treated by catheter-based
therapy before they precipitate an ischemic event. At
autopsy, histologic characteristics of such vulnerable plaques,
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to the contents of this paper to disclose.a large necrotic core and a thin (<65 mm) ﬁbrous cap
weakened by inﬁltration with macrophages (2). During life,
thin-cap ﬁbroatheromas may be detected invasively using
virtual histology (VH) intravascular ultrasonography
(IVUS), which displays them as plaques with lipid adjacent
to the lumen. The PROSPECT study determined that
plaques with the VH thin-cap ﬁbroatheromas pattern, pla-
que burden >70%, and maximal luminal area <4 mm2 were
most likely to lead to events. Other invasive techniques are
under development and study, such as near-infrared spec-
troscopy (3), in which the arterial wall is interrogated for
lipid deposits, and optical coherence tomography (4), in
which reﬂected light generates high-resolution images of
superﬁcial layers of the vessel wall. Noninvasively, by CTA,
visualized vulnerable plaque features include low-attenuation
(HU <30) sometimes in a “signet ring pattern” (5), positive
remodeling, and spotty calciﬁcation (6).
Yet, it is unlikely that any approach based on the detec-
tion of individual vulnerable plaques will bear clinical fruit in
the foreseeable future (7). Most plaque disruptions are silent
events. Even if thrombus forms, in most cases there is no
luminal obstruction (8–10) and no ischemia, and the
disruption merely results in unnoticed plaque growth.
Furthermore, serial study by IVUS suggests that noncalciﬁed
plaque with vulnerable characteristics by VH-IVUS may
evolve into a more stable appearance and vice versa, even in
a period as short as 12 months (11). Therefore, even if new
imaging techniques are successful in more accurately iden-
tifying plaques that may rupture, any attempt at catheter-
based therapy would need to be applied to many, many
sites before a single event is prevented.
The solution is to consider the vulnerability of the entire
patient rather than that of the individual plaque. This allows
the taking into account of susceptibility of the patient to
thrombosis (7,12). In addition, the obvious other factor to
consider is the total quantity of high-risk plaque material,
which determines the probability that plaque disruption will
occur at some unknown site or other. Ideally, there would be
a global vulnerable plaque “score” analogous to the calcium
score, but sensitive to the plaque characteristics that are
directly responsible for ischemic events rather than to calcium,
an indirect marker of disease activity. To have the greatest
impact, our efforts at deﬁning vulnerability should be focused
on determining patient risk with a thrombosis/plaque score so
that systemic rather than local therapy of appropriate
aggressiveness can be applied. The high-scoring patient would
need the strictest low-density lipoprotein and blood pressure
management, the strongest antiplatelet regimen, and the
broadest blockade of the renin-angiotensin system. Future
therapies that are successful at reducing residual risk with
treatment directed at high-density lipoprotein (13) and
suppression of inﬂammation (14) might also be heaped upon
this unfortunate patient. The patientwith a low scoremight be
adequately protected with an aspirin alone.
Versteylen et al. (1) have made progress toward this
personalization of risk assessment by following up 1,650
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2307patients with stable chest pain who had undergone cardiac
CTA for an average of 26 months and comparing the 26
patients who had an acute coronary syndrome (ACS) with
101 controls with coronary artery disease randomly selected
from the non-ACS group. Coronary arteries were evaluated
with a whole-heart quantitative technique, using a commer-
cially available software package that draws contours along
plaques of different densities and allows quantiﬁcation of
global and maximal plaque characteristics. Several similar
packages are on the market and have been validated by
comparison to IVUS (15,16). The investigators found that
the most predictive global parameters were the total volume
of noncalciﬁed plaque, the total volume of all plaque, and the
total number of plaques. The most predictive local param-
eters were the presence of plaque with the highest volume,
and lesions with the highest plaque burden. Receiving
honorable mention were plaques with the highest area, the
highest noncalciﬁed percentage, the lowest attenuation, and
the highest remodeling index. These ﬁndings are consistent
with the well-accepted concept that noncalciﬁed plaque is
the usual culprit and that calciﬁed plaque is a marker only of
disease burden and not a major player in the mechanism of
acute ischemic events. This work conﬁrms and extends the
ﬁndings of Kristensen et al. (17), who showed that in post-
ACS patients (a higher risk population than that studied
here) multivariate analysis yielded the same 2 parameters as
the major determinants of prognosis: noncalciﬁed plaque
volume and total plaque volume. Therefore, it appears that
elements of a new scoring system should certainly include
total volume of noncalciﬁed plaque and maximal volume or
plaque burden of an individual plaque.
One new contribution of Versteylen et al. (1) is the
ﬁnding that these parameters can be measured semi-
automatically, which brings an otherwise time-consuming
measurement a step closer to clinical utility. The authors
did not describe the average time to make and edit these
measurements. The software that requires the least human
correction to correspond with a visual assessment, and that
provides tools for the fastest editing, will prevail here.
Conventional interpretation of CTA includes calcium
scoring, a description of plaques and their characteristics, and
an assessment of stenosis with designation as nonobstructive,
1-, 2-, or 3-vessel disease (18). Versteylen et al. (1) here
demonstrate that this new type of quantitative analysis
provides prognostic information that improves upon
conventional interpretation of CTA: the area under the
receiver-operating characteristics curve for predicting events
was increased from 0.64 to 0.79 when these new quantitative
parameters were applied. These data suggest that the multiple
studies showing accurate prediction of prognosis by cardiac
CT using conventional interpretation (19–22) have not yet
fully tapped the power of the technique. For example, the
CONFIRM (Coronary CT Angiography Evaluation for
Clinical Outcomes: An International Multicenter Registry)
study has provided multicenter prospective data in 24,775
patients, showing decreasing survival in nonobstructive versus1-vessel obstructive, versus 2-vessel obstructive, and versus
3-vessel obstructive diseasedan analysis relying on old-
fashioned “lumenography” rather than on plaque within the
arterial wall (23). Although a semiquantitative “segment
involvement score” (SIS) also was reported, a more quanti-
tative assessment of noncalciﬁed plaque in that and other large
datasets is likely to provide new insights.
Coronary artery calcium (CAC) scoring has greatly reﬁned
our ability to predict risk in the asymptomatic population, and
it now carries a IIa guideline recommendation for patients at
intermediate Framingham risk score, in which half can be
correctly reclassiﬁed into high or low categories (24). The
guidelines give a IIb recommendation for patients at low to
moderate risk. Now that CTA can be performed with a radi-
ation dose comparable to that of calcium scoring (25), would
a risk score based on noncalciﬁed plaque provide better clas-
siﬁcation of asymptomatic patients? Choi et al. (26) followed
up 1,000 asymptomatic patients and did not ﬁnd an advantage
of CT angiography over CAC for screening, but theirs was
a very low-risk population and only 15 events, including only 1
ACS, occurred during the 17 months of follow-up reported.
Recent ﬁndings from the CONFIRM registry also suggest no
advantage of CTA over CAC in 7,590 subjects from this
population (27), but this was a conventional CT analysis that
did not include noncalciﬁed plaque volumes or other global
parameters introduced more recently. Perhaps this result
would change if the data were reanalyzed with these
measurements included. However, from a practical point of
view, the simplicity, speed, and low cost of calcium imaging
will make it hard to beat as a screening tool for low-risk
populations. It is in higher risk populations, such as patients
with stable angina, where CT angiography with conventional
interpretation is already known to predict adverse outcomes
(19–22,28). In post-ACS patients, the augmented power of
plaque-scored CTA may become evident. Calcium scoring
has little role in these populations.
Availability of a plaque score may resolve some funda-
mental contradictions in cardiology. For instance, we clini-
cians pay lip service to the fact that most ischemic events
result from disruption of nonstenotic plaques (12), yet we
manage patients on the basis of single-, double-, or triple-
vessel stenotic disease. The true importance of stenosis
versus plaque volume is unknown. While it is true that CT
studies (20) have conﬁrmed catheterization studies showing
a major difference in prognosis between nonobstructive,
single-, double-, and triple-vessel disease, multivessel
patients have more nonobstructive plaque as well, which
could be the real determinant of prognosis. An outcome
study reporting both plaque measures and stenosis could
reveal whether 1 or both aspects of the disease have an
independent prognostic effect.
Another issue needing clariﬁcation is how to select the
optimal method for revascularization when it is deemed to
be necessary. We currently decide whether to use percuta-
neous coronary intervention versus coronary artery bypass
graft surgery on the basis of technical features, the
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disease, and other factors captured by the score based on the
SYNTAX (Synergy Between PCI With TAXUS and
Cardiac Surgery) study (29). Wouldn’t it make more sense
to stent arteries in which the atherosclerosis is truly focal,
and bypass those with an extensive longitudinal extent of
plaque that could rupture anywhere along the vessel, thereby
treating the whole artery? That is, a revised SYNTAX score
including the vessel plaque volume might improve the
selection process. Finally, research studies of new drugs or
procedures to treat coronary artery disease would require far
fewer patients if they were directed at a select group with
a predictable high incidence of acute coronary syndrome.
Studies like that of Versteylen et al. (1), in which the
diffuse nature of coronary atherosclerosis is recognized and
measured, lay the groundwork for development of a new and
more logical way to predict the risk of coronary events. The
prescription of personalized, targeted treatment based on
CT imaging is a promising direction. Large, well-designed
studies will be necessary to learn how to best use this new
information.
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